Skip Nav Destination
Issues
1 October 2020
-
Cover Image
Cover Image
In this issue of Molecular Cancer Therapeutics, Vijayaraghavan and colleagues outline the mechanism of an anti-EGFR/anti-cMET bispecific antibody, Amivantamab. The anti-tumor efficacy of amivantamab required the Fc-dependent trogocytosis, pictured on our cover. In trogocytosis, macrophages (shown in green) acquired fragments of opsonized tumor cell membranes (shown in orange). Read the full article on page 2044. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo
Yamini M. Ohol; Michael T. Sun; Gene Cutler; Paul R. Leger; Dennis X. Hu; Berenger Biannic; Payal Rana; Cynthia Cho; Scott Jacobson; Steve T. Wong; Jerick Sanchez; Niket Shah; Deepa Pookot; Betty Abraham; Kyle Young; Silpa Suthram; Lisa A. Marshall; Delia Bradford; Nathan Kozon; Xinping Han; Akinori Okano; Jack Maung; Christophe Colas; Jacob Schwarz; David Wustrow; Dirk G. Brockstedt; Paul D. Kassner
The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA
Yohei Sugimoto; Yoshiki Katsumi; Tomoko Iehara; Daisuke Kaneda; Chihiro Tomoyasu; Kazutaka Ouchi; Hideki Yoshida; Mitsuru Miyachi; Shigeki Yagyu; Ken Kikuchi; Kunihiko Tsuchiya; Yasumichi Kuwahara; Toshiyuki Sakai; Hajime Hosoi
Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2
Qiaqia Li; Kilia Y. Liu; Qipeng Liu; Guangyu Wang; Weihua Jiang; Qingshu Meng; Yang Yi; Yongyong Yang; Rui Wang; Sen Zhu; Chao Li; Longxiang Wu; Dongyu Zhao; Lin Yan; Lili Zhang; Jung-Sun Kim; Xiongbing Zu; Anthony J. Kozielski; Wei Qian; Jenny C. Chang; Akash Patnaik; Kaifu Chen; Qi Cao
Large Molecule Therapeutics
Author Choice
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
Smruthi Vijayaraghavan; Lorraine Lipfert; Kristen Chevalier; Barbara S. Bushey; Benjamin Henley; Ryan Lenhart; Jocelyn Sendecki; Marilda Beqiri; Hillary J. Millar; Kathryn Packman; Matthew V. Lorenzi; Sylvie Laquerre; Sheri L. Moores
PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
Edmund I. Graziani; Matthew Sung; Dangshe Ma; Bitha Narayanan; Kimberly Marquette; Sujiet Puthenveetil; L. Nathan Tumey; Jack Bikker; Jeffrey Casavant; Eric M. Bennett; Manoj B. Charati; Jonathon Golas; Christine Hosselet; Cynthia M. Rohde; George Hu; Magali Guffroy; Hadi Falahatpisheh; Martin Finkelstein; Tracey Clark; Frank Barletta; Lioudmila Tchistiakova; Judy Lucas; Edward Rosfjord; Frank Loganzo; Christopher J. O'Donnell; Hans-Peter Gerber; Puja Sapra
Author Choice
Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts
Adnan O. Abu-Yousif; Donna Cvet; Melissa Gallery; Bret M. Bannerman; Michelle L. Ganno; Michael D. Smith; Katharine C. Lai; Thomas A. Keating; Bradley Stringer; Afrand Kamali; Kurt Eng; Secil Koseoglu; Andy Zhu; Cindy Q. Xia; Melissa Saylor Landen; Maria Borland; Robbie Robertson; Jayaprakasam Bolleddula; Mark G. Qian; Jennifer Fretland; O. Petter Veiby
Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies
Haihui Lu; Ryan D. Molony; Dongshu Chen; Sunyoung Jang; Babette Wolf; Stefan Ewert; Meghan Flaherty; Fangmin Xu; Sinan Isim; Yeonju Shim; Christina Dornelas; Nicole Balke; Xavier Charles Leber; Meike Scharenberg; Johanna Koelln; Eugene Choi; Rebecca Ward; Jennifer Johnson; Thomas Calzascia; Isabelle Isnardi; Juliet A. Williams; Pieter L. Lindenbergh; Niels W.C.J. van de Donk; Tuna Mutis; Heather Huet; Emma Lees; Matthew J. Meyer
Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody
Amir A. Al-Khami; Sawsan Youssef; Yasmina Abdiche; HoangKim Nguyen; Joyce Chou; Christopher R. Kimberlin; Sherman M. Chin; Cris Kamperschroer; Bart Jessen; Brent Kern; Natalija Budimir; Christopher P. Dillon; Allison Xu; Jerry D. Clark; Jeffrey Chou; Eugenia Kraynov; Arvind Rajpal; John C. Lin; Shahram Salek-Ardakani
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
Mark G. Anderson; Hugh D. Falls; Michael J. Mitten; Anatol Oleksijew; Kedar S. Vaidya; Erwin R. Boghaert; Wenqing Gao; Joann P. Palma; Diana Cao; Puey-Ling Chia; Thomas John; Hui K. Gan; Andrew M. Scott; Edward B. Reilly
Author Choice
Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism
Marije B. Overdijk; Kristin Strumane; Frank J. Beurskens; Antonio Ortiz Buijsse; Claudine Vermot-Desroches; Boris S. Vuillermoz; Thessa Kroes; Bart de Jong; Naomi Hoevenaars; Richard G. Hibbert; Andreas Lingnau; Ulf Forssmann; Janine Schuurman; Paul W.H.I. Parren; Rob N. de Jong; Esther C.W. Breij
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Author Choice
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers
Paul Riviere; Aaron M. Goodman; Ryosuke Okamura; Donald A. Barkauskas; Theresa J. Whitchurch; Suzanna Lee; Noor Khalid; Rachel Collier; Manvita Mareboina; Garrett M. Frampton; David Fabrizio; Andrew B. Sharabi; Shumei Kato; Razelle Kurzrock
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib
Yingmiao Liu; Jing Lyu; Kirsten Bell Burdett; Alexander B. Sibley; Ace J. Hatch; Mark D. Starr; John C. Brady; Kelli Hammond; Federica Marmorino; Daniele Rossini; Richard M. Goldberg; Alfredo Falcone; Chiara Cremolini; Kouros Owzar; Anastasia Ivanova; Dominic T. Moore; Michael S. Lee; Hanna K. Sanoff; Federico Innocenti; Andrew B. Nixon
Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors
E. Gabriela Chiorean; Susan M. Perkins; R. Matthew Strother; Anne Younger; Jennifer M. Funke; Safi G. Shahda; Noah M. Hahn; Kumar Sandrasegaran; David R. Jones; Todd C. Skaar; Bryan P. Schneider; Christopher J. Sweeney; Daniela E. Matei
Cancer Biology and Translational Studies
Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy
Christian K. Werner; Uchechi J. Nna; Hanshi Sun; Kari Wilder-Romans; Joseph Dresser; Ayesha U. Kothari; Weihua Zhou; Yangyang Yao; Arvind Rao; Stefanie Stallard; Carl Koschmann; Tarik Bor; Waldemar Debinski; Alexander M. Hegedus; Meredith A. Morgan; Sriram Venneti; Edwina Baskin-Bey; Daniel E. Spratt; Howard Colman; Jann N. Sarkaria; Arul M. Chinnaiyan; Joel R. Eisner; Corey Speers; Theodore S. Lawrence; Roy E. Strowd; Daniel R. Wahl
Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy
Masahiro Shibata; Akira Ooki; Yoshikuni Inokawa; Pritam Sadhukhan; M. Talha Ugurlu; Evgeny Izumchenko; Enrico Munari; Giuseppe Bogina; Charles M. Rudin; Edward Gabrielson; Anju Singh; Mohammad O. Hoque
The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma
Florencia Rago; GiNell Elliott; Ailing Li; Kathleen Sprouffske; Grainne Kerr; Aurore Desplat; Dorothee Abramowski; Julie T. Chen; Ali Farsidjani; Kay X. Xiang; Geoffrey Bushold; Yun Feng; Matthew D. Shirley; Anka Bric; Anthony Vattay; Henrik Möbitz; Katsumasa Nakajima; Christopher D. Adair; Simon Mathieu; Rukundo Ntaganda; Troy Smith; Julien P.N. Papillon; Audrey Kauffmann; David A. Ruddy; Hyo-eun C. Bhang; Deborah Castelletti; Zainab Jagani
Author Choice
Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer
Yoshihisa Kawai; Kenjiro Imada; Shusuke Akamatsu; Fan Zhang; Roland Seiler; Tetsutaro Hayashi; Jeffrey Leong; Eliana Beraldi; Neetu Saxena; Alexander Kretschmer; Htoo Zarni Oo; Alberto Contreras-Sanz; Hideyasu Matsuyama; Dong Lin; Ladan Fazli; Colin C. Collins; Alexander W. Wyatt; Peter C. Black; Martin E. Gleave
Models and Technologies
Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis
Joy M. Gary; John K. Simmons; Jinfei Xu; Shuling Zhang; Tyler J. Peat; Nicholas Watson; Benjamin J. Gamache; Ke Zhang; Alexander L. Kovalchuk; Aleksandra M. Michalowski; Jin-Qiu Chen; Tuddow Thaiwong; Matti Kiupel; Snehal Gaikwad; Maudeline Etienne; R. Mark Simpson; Wendy Dubois; Joseph R. Testa; Beverly A. Mock
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.